Hemophilia a - Recombinant Factor Viii. 2026 Tender - 146662498

Procurement Summary

Country: Czech Republic

Summary: Hemophilia a - Recombinant Factor Viii. 2026

Deadline: 09 Sep 2026

Posting Date: 06 Aug 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 146662498

Document Ref. No.: 546770-2026

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: CZK 753270

CPV Classification

33621000 - Medicinal products for the blood and blood-forming organs

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_details

Login to see details

Tender Details

Coagulation factor VIII - recombinant Esperoct for unmedicated patients from 13 years of age who are pretreated with FVIII from plasma or rFVIII min 150 exposure days Hemophilia A - Coagulation factor VIII - recombinant with a longer biological half-life - for patients from 13 years of age who are pretreated with FVIII from plasma or rFVIII min 150 exposure days Hemophilia A - Coagulation factor VIII - recombinant with a longer biological half-life - for patients from 13 years of age without pretreatment with FVIII from plasma or rFVIII Hemophilia A-Coagulation Factor VIII - recombinant with a longer biological half-life - for patients under 12 years of age Recombinant preparations for the prevention and treatment of bleeding in hemophilia A, as well as in patients with hemophilia A with an inhibitor against FVIII (titer up to 5 BU) of the 3rd and higher generations They are the subject of public contracts recurring deliveries of medicinal products meeting the requirements of SÚKL. The subject of the public contract is the repeated supplies of coagulation factor VIII - recombinant Esperoct for unmedicated patients from the age of 13 who are pretreated with FVIII from plasma or rFVIII min 150 exposure days meeting the requirements of SÚKL. The subject of the public contract is the repeated supplies of hemophilia A-Coagulation factor VIII - recombinant with a longer biological half-life - for patients from 13 years of age who are pretreated with FVIII from plasma or rFVIII min 150 exposure days meeting the requirements of SÚKL. The subject of the public contract is the recurring supply of coagulation factor VIII - recombinant with a longer biological half-life - for patients from 13 ...
Document Type: Contract Notice Reference Number: VZ-2026-000767 Contract Type: supplies Estimated Value: 753270 - CZK Authority Type: body-pl-cga Doc Title: Hemofilie A - Rekombinantní faktor VIII. 2026 Dispatch Date: 2026-08-05 Publish Date: 2026-08-06 Submission Date: 2026-09-09

Documents

 Tender Notice